<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20210808052106N2</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2023-02-27</date_registration>
      <primary_sponsor>National Research Center of Iran Health Insurance Organization</primary_sponsor>
      <public_title>Investigating the effect of education in reducing insulin consumption in patients with type 2 diabetes</public_title>
      <acronym></acronym>
      <scientific_title>Investigating the effect of teaching self-care behaviors on reducing insulin consumption in patients with type 2 diabetes covered by the health insurance</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2023-02-20</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>62</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/68376</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Double blinded, Placebo: Not used, Assignment: Parallel, Purpose: Supportive, Randomization description: Eligible participants will be randomly assigned to intervention and control groups using random block method by RAS (Random Allocation Software) and 1:1 allocation ratio by a person not involved in the research.
In order to hide the allocation of groups based on a random sequence, the allocation is written by a person not involved in the research in terms of numbers on a paper and sealed in a matte envelope. So that the researcher and the analyst will not know about the allocation of groups, Blinding description: In order to hide the allocation of groups based on a random sequence, the allocation is written by a person not involved in the research in terms of numbers on a paper and sealed in a matte envelope. So that the researcher and the analyst will not know about the allocation of groups.</study_design>
      <phase>N/A</phase>
      <hc_freetext>Type 2 diabetes.</hc_freetext>
      <i_freetext>Intervention 1: The group receiving lifestyle, diet and physical activity education. The people of the intervention group will be prescribed a diet containing 60% carbohydrates, 25% fat and 15% protein, 500 kilocalories less than the calculated daily energy, along with general healthy nutrition education based on increasing the consumption of vegetables and legumes and reducing the consumption of sweets and saturated fats. . This group will participate in aerobic exercise for 12 weeks and three sessions per week. The exercise will include brisk walking with 60% heart rate intensity for 45 minutes. The training sessions will include how to inject insulin by a diabetes doctor, healthy nutrition by a nutrition consultant, and physical activity by a sports consultant at the beginning of the study for 6 hours. Intervention 2: Control group: During the study, this group will not receive diet and training, but at the end of the study, a training session along with a lifestyle training brochure will be provided to them.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Yes - There is a plan to make this available</results_IPD_plan>
      <results_IPD_description>What will be shared:
Part of the data, such as information about the main outcome

When:
Access period starts 6 months after the results are published

To whom:
Researchers working in academic and scientific institutions

Conditions:
Research using our study from another dimension

Where to obtain:
Ms. Soraya Moradi Analyst of the study Tel:009851040444 moradi.s@ihio.gov.ir

How to obtain:
E-mail from the academic researcher and with the authentication of the researcher is possible within one month

Comments:
</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Leila Javadi</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>No.35, Rushdieh Alley, Saadi St., Valiasr</address>
        <city>Tabriz</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>5157936534</zip>
        <telephone>+98 41 3333 1633</telephone>
        <email>Javadi.l@ihio.gov.ir</email>
        <affiliation>Health Insurance Organization</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Leila Javadi</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>No.35, Rushdieh Alley, Saadi Ave, valiasr</address>
        <city>Tabriz</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>5157936534</zip>
        <telephone>+98 41 3333 1633</telephone>
        <email>Javadi.l@ihio.gov.ir</email>
        <affiliation>Health Insurance Organization</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Patients with type 2 diabetes should be both men and women in the age range of 35-65
Patients are covered by health insurance</inclusion_criteria>
      <agemin>35 years</agemin>
      <agemax>65 years</agemax>
      <gender>Both</gender>
      <exclusion_criteria>Lack of consent to participate or continue the plan Migration
Having mental disorders and movement disorders
Having an underlying disease such as debilitating cardiovascular disease</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>E11</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Type 2 diabetes mellitus</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Lifestyle</i_code>
      <i_code>N/A</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>The group receiving lifestyle, diet and physical activity education. The people of the intervention group will be prescribed a diet containing 60% carbohydrates, 25% fat and 15% protein, 500 kilocalories less than the calculated daily energy, along with general healthy nutrition education based on increasing the consumption of vegetables and legumes and reducing the consumption of sweets and saturated fats. . This group will participate in aerobic exercise for 12 weeks and three sessions per week. The exercise will include brisk walking with 60% heart rate intensity for 45 minutes. The training sessions will include how to inject insulin by a diabetes doctor, healthy nutrition by a nutrition consultant, and physical activity by a sports consultant at the beginning of the study for 6 hours.</i_keyword>
      <i_keyword>Control group: During the study, this group will not receive diet and training, but at the end of the study, a training session along with a lifestyle training brochure will be provided to them.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Fasting blood sugar. Timepoint: The beginning and end of the study. Method of measurement: Spectrophotometric method.</prim_outcome>
      <prim_outcome>Two-hour blood sugar. Timepoint: The beginning and end of the study. Method of measurement: Spectrophotometric method.</prim_outcome>
      <prim_outcome>HbA1c. Timepoint: The beginning and end of the study. Method of measurement: Spectrophotometric method.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome>Pen insulin dosage. Timepoint: The beginning and end of the study. Method of measurement: Electronic prescription system.</sec_outcome>
      <sec_outcome>The average score of anthropometric indices (weight and body mass index) in the study groups. Timepoint: The beginning and end of the study. Method of measurement: Weighed by a Saka scale with an accuracy of 0.1 Kg, height with stadiometer and body mass index are obtained by dividing a person's weight in kilograms by the second power (x²) of his height in meters.</sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>National Research Center of Iran Health Insurance Organization</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2023-01-09</approval_date>
        <contact_name>thics committee of Tabriz University of Medical Sciences</contact_name>
        <contact_address>NO.35, Roshdie Alley, Saadi Ave, valiasr Tabriz East Azarbaijan Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
